

MEMORANDUM OF UNDERSTANDING (MoU)

Institute of Cytology and Preventive Oncology (ICPO)

Indian Council of Medical Research (ICMR)

I-7, Sector-39, NOIDA

AND

Rajiv Gandhi Cancer Institute and Research Center

(RGCI&RC)

Sector-V, Rohini, Delhi

01st September, 2014

MEMORANDUM OF UNDERSTANDING (MoU)

This is **MEMORANDUM OF UNDERSTANDING (MoU)** made and entered into effect on of the **01st September, 2014**

BETWEEN

2. Areas of collaboration

- **Cervical, breast, oral and other cancers.**
- **Molecular Epidemiology**
- **Clinical and pre-clinical trials of potential anti-cancer therapeutics including cancer vaccines**
- **Cancer diagnosis and molecular markers**
- **Cancer stem cell research**
- **Understanding molecular mechanisms of carcinogenesis**
- **Joint organization of Symposia, Seminar, Workshops and Lectures**

3. Scientific coordination and Joint Management Committee (JMC)

3.1 Collaborative projects will be coordinated jointly by ICMR and RGCI & RC.

3.2 Scientists from ICPO (ICMR) and RGCI & RC & their partners will form joint interdisciplinary research teams.

3.3 A Joint Management Committee (JMC) will be constituted. Members of the JMC will be selected based on a mutual understanding between ICPO (ICMR) and RGCI & RC.

3.4 The Joint Management Committee will meet at least every six months and whenever need arise. Meetings can be held by any means of communication (e.g. telephone conferences). Annual personal meetings at alternate locations shall be held at mutual convenience.

3.5 Decision of the Joint Management Committee shall be made consensually.

4. Job responsibility on collaborative projects

4.1 Role of Party (A): ICPO

- To do study on molecular epidemiology and molecular interpretation of data.
- To undertake molecular study on development of cancers (like breast cancer etc.).
- To undertake molecular investigations for diagnosis/prognosis for specific types of cancer

- iv. To develop molecular techniques for diagnosis and treatments of cancer.
- v. To develop reagents, vaccines etc.

4.2 Role of Party (B) RGCI

- i To undertake clinical diagnosis and clinico-epidemiological studies.
- ii. To collect clinical details & specimens and results especially those done by molecular technology.
- iii. To collect and analyze data from patients.
- iv. To undertake clinical trials for cancer therapeutic studies and vaccines.
- v. To evaluate reagents, vaccines etc. in collaboration with ICPO.

4.3 Any molecular technology applied for diagnosis or therapy which is not charged for by the ICPO, will also not be charged from the patients by RGCI&RC.

5. Research Work

5.1 Institute shall commence the performance of the projects promptly and shall use reasonable endeavors to perform such projects substantially in accordance with the terms and conditions of this MOU. The two institutes may however at any time amend the project by mutual written consent.

5.2 Both Institutes will independently get the projects/proposals cleared by their respective IRB/Ethical Committees.

5.3 Investigators from both the institutes should have access to all the raw data, molecular findings, methodologies, patients' details, test reports and other related materials associated with the collaborative project.

5.4 In the event that the investigator becomes unable to continue a project and a mutually acceptable substitute is not available, the Institute A and/or the Institute B shall have the option to terminate the project as per the terms and conditions of the clause 12. In such cases, the responsibility of Non-performance will solely be of the individual investigator(s) and their respective institute.

6. Reporting

6.1 In order to define the common objectives, the parties engage themselves to confer together periodically.

- 6.2** The parties shall disclose to each other all other information and material which is necessary for efficient functioning of the collaborative projects, unless such disclosure would violate a reasonable confidentiality interest as agreed by both parties or a secrecy obligation to a third party.
- 6.3** The exchanges and the actions carried out in this MoU will be reported to the Joint Management Committee.